Brain-Disabling Treatments in Psychiatry

Drugs, Electroshock, and the Psychopharmaceutical Complex

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Brain-Disabling Treatments in Psychiatry

Drugs, Electroshock, and the Psychopharmaceutical Complex

Second Edition

Author

Peter R. Breggin, MD

Description

From the author of Toxic Psychiatry and Talking Back to Prozac:

Peter Breggin is the conscience of American psychiatry. Once more he updates us on the real evidence with respect to the safety and effectiveness of specific psychiatric medications and ECT. This information is needed by all mental health professionals, as well as patients and families." --Bertram Karon, Ph.D., Professor of Psychology, Michigan State University, Author of The Psychotherapy of Schizophrenia

"Nowhere does false medical thinking do more harm than in the modern psychiatric argument that mental illness is easily diagnosed and then cured by a side-effect free drug. Nowhere is the correct psychiatric thinking more evident than in the books by Peter Breggin. -- William Glasser, MD, psychiatrist, author of Reality Therapy

In Brain Disabling Treatments in Psychiatry, renowned psychiatrist Peter R. Breggin, M.D., presents startling scientific research on the dangerous behavioral abnormalities and brain dysfunctions produced by the most widely used and newest psychiatric drugs such as Prozac, Paxil, Zoloft, Cymbalta, Effexor, Xanax, Ativan, Ritalin, Adderall, Concerta, Strattera, Risperdal, Zyprexa, Geodon, Abilify, lithium and Depakote.

Many of Breggin's earlier findings have improved clinical practice, led to legal victories against drug companies, and resulted in FDA-mandated changes in what the manufacturers must admit about their drugs. Yet reliance on these drugs has continued to escalate in the last decade, and drug company interests have overwhelmed psychiatric practice.

This greatly expanded second edition, supported by the latest evidence-based research, shows that psychiatric drugs achieve their primary or essential effect by causing brain dysfunction, and that they tend to do far more harm than good.

Chapters covering every new antidepressant and stimulant drug
Twenty new guidelines for how to conduct non-drug therapy
A chapter describing how to safely withdraw from psychiatric drugs
A discussion of "medication spellbinding," explaining how patients fail to appreciate their drug-induced mental dysfunctions
Documentation of how the drug companies control research and the flow of information about psychiatric treatments

Contents

The Brain-Disabling, Spellbinding Effects of Psychiatric Drugs
Deactivation Syndrome (Chemical Lobotomy) Caused by Neuroleptics
Neuroleptic-Induced Anguish, Including Agitation, Despair, and Depression
Severe and Potentially Irreversible Neurological Syndromes (Tardive Dyskinesia and Neuroleptic Malignant Syndrom) Caused by Neuroleptics
Neuroleptic-Induced Neurotoxicity, Brain Damage, Persistent Cognitive Deficits, Dementia, and Psychosis
Recent Developments in Antidepressant Label Changes
Antidepressant-Induced Mental, Behavioral and Cerebral Abnormalities
Lithium and Other Drugs for Bipolar Disorder
Electroconvulsive Therapy (ECT) for Depression
From Attention-Deficit/Hyperactivity Disorder (ADHD) to Bipolar Disorder: Diagnosing America's Children
Stimulant-Induced Brain Damage, Brain Dysfunction, and Psychiatric Adverse Reactions
Antianxiety Drugs, Including Behavioral Abnormalities Caused by Xanax and Halcion
The Food and Drug Administration (FDA) and the National Institute of Mental Health (NIMH): Drug Company Advocates
Drug Company Deceptions
How to More Safely Stop Taking Psychiatric Drugs
Failed Promises, Last Resorts, and Psychotherapy

Authors

Peter R. Breggin, MD, is a Harvard-trained psychiatrist and former full-time consultant at NIMH. He is in private practice in Ithaca, New York, and the author of dozens of scientific articles and more than twenty books.

Product Details